Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
0.7432
-0.0214 (-2.80%)
At close: Dec 11, 2025, 4:00 PM EST
0.7600
+0.0168 (2.26%)
Pre-market: Dec 12, 2025, 6:30 AM EST
Harvard Bioscience Revenue
Harvard Bioscience had revenue of $20.59M in the quarter ending September 30, 2025, a decrease of -6.28%. This brings the company's revenue in the last twelve months to $87.37M, down -10.60% year-over-year. In the year 2024, Harvard Bioscience had annual revenue of $94.14M, down -16.14%.
Revenue (ttm)
$87.37M
Revenue Growth
-10.60%
P/S Ratio
0.38
Revenue / Employee
$246,115
Employees
355
Market Cap
33.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | 116.18M | -4.60M | -3.81% |
| Dec 31, 2018 | 120.77M | 43.37M | 56.02% |
| Dec 31, 2017 | 77.41M | -27.11M | -25.94% |
| Dec 31, 2016 | 104.52M | -4.14M | -3.81% |
| Dec 31, 2015 | 108.66M | 1,000.00 | - |
| Dec 31, 2014 | 108.66M | 3.49M | 3.32% |
| Dec 31, 2013 | 105.17M | -6.00M | -5.40% |
| Dec 31, 2012 | 111.17M | 2.31M | 2.12% |
| Dec 31, 2011 | 108.86M | 685.00K | 0.63% |
| Dec 31, 2010 | 108.18M | 22.41M | 26.12% |
| Dec 31, 2009 | 85.77M | -2.28M | -2.59% |
| Dec 31, 2008 | 88.05M | 4.64M | 5.57% |
| Dec 31, 2007 | 83.41M | 7.23M | 9.49% |
| Dec 31, 2006 | 76.18M | 8.75M | 12.98% |
| Dec 31, 2005 | 67.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HBIO News
- 5 weeks ago - Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Harvard Bioscience Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET - GlobeNewsWire
- 3 months ago - Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States - GlobeNewsWire
- 3 months ago - Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors - GlobeNewsWire
- 4 months ago - Harvard Bioscience, Inc. (HBIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Harvard Bioscience Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET - GlobeNewsWire